Press Release

Launch of Jublia in KoreaMay 31, 2017

Tokyo, May 31, 2017 - Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) announced that Kaken’s licensing partner, Dong-A ST Co., Ltd. (“Dong-A ST”, head office Dongdaemun-gu, Seoul; President Min Jang Seong) plans to launch Jublia, a topical formulation drug for Onychomycosis (generic name: efinaconazole; product name in Japan: Clenafin®) on June 1, 2017 in Korea.

Kaken and Dong-A ST concluded a license agreement on May 31 2016 granting Dong-A ST exclusive rights for the development and sale of Jublia in Korea, and Dong-A ST obtained approval on May 16, 2017, from Korea’s Ministry of Food and Drug Safety (MFDS) for the sale of Jublia.

About Dong-A ST

  • Company name
    Dong-A ST Co., Ltd.
    Min Jang Seong
    Head Quarter

Back to list